{"id":919558,"date":"2025-12-15T08:06:03","date_gmt":"2025-12-15T13:06:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/"},"modified":"2025-12-15T08:06:03","modified_gmt":"2025-12-15T13:06:03","slug":"bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/","title":{"rendered":"Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BOSTON, Dec.  15, 2025  (GLOBE NEWSWIRE) &#8212; Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT.<\/p>\n<p>A live webcast of the presentation will be accessible through the Investor Relations section of Bicara\u2019s website under Events and Presentations. A replay of the webcast will be archived and available following the event.<\/p>\n<p>\n        <strong>About Bicara Therapeutics <\/strong><br \/>\n        <br \/>Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara\u2019s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-\u03b2). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-\u03b2 signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rfDHp_Q6TRvwwyhxEThm6I9g5aRFLGMxYfCDevFVRc6dbDrm_2z8XFphFrf2HAFm5M4mE58xvaN1vwkK77CYAg==\" rel=\"nofollow\" target=\"_blank\">www.bicara.com<\/a>\u00a0or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wNjnCnAj-8l0MDTF2qrgT6-NKwfPI9Dx_Qag3keyTwfqrAgJZct7mjIKnPg6Zs-zz8DDBXTgqbiCMCbKolF_KBEBhgG4FC15jWajTc-QfQ2i7tuBXVFYQ0w2Kaxk1ETm\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=plW0Pmyb_aBM1-pfXARu8hYriW4JyNd2lJvOszSuGo2nSRCh8Cyi-AcMUo9jhFH6Ot0ZyvtG3wZ8cTFW6ENanw==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Jenna Cohen <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZFU6u1Mh_9M5Xkw9rp_1MeyAZzPXnKCM7W_xvzES8qnMpWnslVrkaGMPtWO8EhPnyjq-4PXJiMqI4vUcC5THEQ==\" rel=\"nofollow\" target=\"_blank\">IR@bicara.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Amanda Lazaro<br \/>1AB<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u4mIEtAzxiu7B8oRc3MnMCovLivOFUqWAn6DAD3QiTZ3Gta-BR1r5qg8MsKVxh-f_URnoYWZT14zHca7rLtC6_lovZW2M-iEGIbTJGDcCxk=\" rel=\"nofollow\" target=\"_blank\">Amanda@1abmedia.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTQ0NCM3MzE5NjM0IzIyNTA4NzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmMyYThlN2ItZWM3NC00OWU1LWJmZWEtYWQ4ODY5YzdlNTBkLTEyNjI0MjctMjAyNS0xMi0xNS1lbg==\/tiny\/Bicara-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) &#8212; Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT. A live webcast of the presentation will be accessible through the Investor Relations section of Bicara\u2019s website under Events and Presentations. A replay of the webcast will be archived and available following the event. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara\u2019s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-919558","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) &#8212; Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT. A live webcast of the presentation will be accessible through the Investor Relations section of Bicara\u2019s website under Events and Presentations. A replay of the webcast will be archived and available following the event. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara\u2019s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody &hellip; Continue reading &quot;Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-15T13:06:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTQ0NCM3MzE5NjM0IzIyNTA4NzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12\",\"datePublished\":\"2025-12-15T13:06:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\\\/\"},\"wordCount\":266,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMTQ0NCM3MzE5NjM0IzIyNTA4NzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\\\/\",\"name\":\"Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMTQ0NCM3MzE5NjM0IzIyNTA4NzQ=\",\"datePublished\":\"2025-12-15T13:06:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMTQ0NCM3MzE5NjM0IzIyNTA4NzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMTQ0NCM3MzE5NjM0IzIyNTA4NzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/","og_locale":"en_US","og_type":"article","og_title":"Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 - Market Newsdesk","og_description":"BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) &#8212; Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT. A live webcast of the presentation will be accessible through the Investor Relations section of Bicara\u2019s website under Events and Presentations. A replay of the webcast will be archived and available following the event. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara\u2019s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody &hellip; Continue reading \"Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-15T13:06:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTQ0NCM3MzE5NjM0IzIyNTA4NzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12","datePublished":"2025-12-15T13:06:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/"},"wordCount":266,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTQ0NCM3MzE5NjM0IzIyNTA4NzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/","name":"Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTQ0NCM3MzE5NjM0IzIyNTA4NzQ=","datePublished":"2025-12-15T13:06:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTQ0NCM3MzE5NjM0IzIyNTA4NzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMTQ0NCM3MzE5NjM0IzIyNTA4NzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-to-present-at-the-j-p-morgan-2026-annual-healthcare-conference-on-monday-january-12\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=919558"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919558\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=919558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=919558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=919558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}